192 related articles for article (PubMed ID: 15561851)
1. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.
Campion JJ; McNamara PJ; Evans ME
Antimicrob Agents Chemother; 2004 Dec; 48(12):4733-44. PubMed ID: 15561851
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.
Campion JJ; Chung P; McNamara PJ; Titlow WB; Evans ME
Antimicrob Agents Chemother; 2005 Jun; 49(6):2189-99. PubMed ID: 15917512
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.
Campion JJ; McNamara PJ; Evans ME
Antimicrob Agents Chemother; 2005 Jan; 49(1):209-19. PubMed ID: 15616298
[TBL] [Abstract][Full Text] [Related]
4. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
5. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
7. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
8. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
Lei Y; Gui X; Feng G
Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
[TBL] [Abstract][Full Text] [Related]
10. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
12. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
[TBL] [Abstract][Full Text] [Related]
14. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.
Chung P; McNamara PJ; Campion JJ; Evans ME
Antimicrob Agents Chemother; 2006 Sep; 50(9):2957-65. PubMed ID: 16940088
[TBL] [Abstract][Full Text] [Related]
17. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
[TBL] [Abstract][Full Text] [Related]
19. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
[TBL] [Abstract][Full Text] [Related]
20. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
